JP5878866B2 - 一酸化窒素治療 - Google Patents
一酸化窒素治療 Download PDFInfo
- Publication number
- JP5878866B2 JP5878866B2 JP2012517624A JP2012517624A JP5878866B2 JP 5878866 B2 JP5878866 B2 JP 5878866B2 JP 2012517624 A JP2012517624 A JP 2012517624A JP 2012517624 A JP2012517624 A JP 2012517624A JP 5878866 B2 JP5878866 B2 JP 5878866B2
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- pharmaceutical composition
- composition according
- therapeutic amount
- solid matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 188
- 238000011282 treatment Methods 0.000 title description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 239000003963 antioxidant agent Substances 0.000 claims description 21
- 235000006708 antioxidants Nutrition 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 20
- 239000000741 silica gel Substances 0.000 claims description 20
- 229910002027 silica gel Inorganic materials 0.000 claims description 20
- 230000003078 antioxidant effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000853 adhesive Substances 0.000 claims description 16
- 230000001070 adhesive effect Effects 0.000 claims description 16
- 239000002840 nitric oxide donor Substances 0.000 claims description 14
- 239000011668 ascorbic acid Substances 0.000 claims description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims description 13
- 229960005070 ascorbic acid Drugs 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- 239000007937 lozenge Substances 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920005992 thermoplastic resin Polymers 0.000 claims description 5
- 229940087168 alpha tocopherol Drugs 0.000 claims description 4
- 239000011888 foil Substances 0.000 claims description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- 239000002478 γ-tocopherol Substances 0.000 claims description 4
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 231100000167 toxic agent Toxicity 0.000 claims description 2
- 238000005245 sintering Methods 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000007789 gas Substances 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000012038 nucleophile Substances 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000011149 active material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- -1 but not limited to Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical group NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000665 anti-chemotactic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003421 catalytic decomposition reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940100563 gas for inhalation Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical group CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- OWKYZAGJTTTXOK-UHFFFAOYSA-N n'-propylpropane-1,3-diamine Chemical group CCCNCCCN OWKYZAGJTTTXOK-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000936 topical exposure Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
- A61M15/085—Fixing means therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
- A61M35/006—Portable hand-held applicators having means for dispensing or spreading integral media using sponges, foams, absorbent pads or swabs as spreading means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M2005/006—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for gases, e.g. CO2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Description
本願は、先の米国特許仮出願番号第61/219,200号(2009年6月22日出願)の利益を主張し、これは参照によりその全体が組み込まれる。
本記載は、治療法に関する。
一酸化窒素ガスの対象への吸入又は局所的曝露は、創傷の治癒の促進、更なる回復のための創傷床の調製、感染及び炎症の低減、並びに肺障害の治療において有益であり得る。しかしながら、典型的な一酸化窒素(NO)療法は、対象にとって毒性となり得る組成物を含み、投与が困難となる場合がある。
概して、対象に一酸化窒素治療を送達する方法は、一酸化窒素放出剤(nitric-oxide releasing agent)及びシリカを含む組成物を対象に投与すること、及び該組成物から治療量の一酸化窒素を放出させることを含む。特定の状況において、シリカゲルは、毒性化合物が対象に侵入するのを防ぐ。他の状況において、該組成物は、酸化防止剤を更に含む。該酸化防止剤は、アスコルビン酸、αトコフェロール又はγトコフェロールであり得る。
種々の実施態様は、一酸化窒素(NO)治療のための方法、組成物及びデバイスに関連する。一般に、一酸化窒素(NO)は、局所的に適用され、吸入され、又は別の方法で個体の肺に送達される。治療用量のNOを与えることで、微生物感染の低減、炎症の低減、コラーゲン形成の制御、及び肺障害の治療を含む様々な利益を提供することができる。加えて、治療用量のNOは、高所病の症状を治療するための酸素治療の必要性、又はより低い高度への早急の下降を補完する、又は最小化するのに使用することができる。治療用量のNOを、対象に毒性を誘発することなく使用することができる。例えば、1ppmより高い、100ppmより高い、又は200ppmより高い濃度を使用することができる。
Claims (19)
- 一酸化窒素放出剤、及び酸化防止剤でフラッシュされたシリカを含む、一酸化窒素治療のための医薬組成物であって、治療量の一酸化窒素が、該組成物から放出されて対象に送達されるように用いられることを特徴とする、前記医薬組成物。
- 前記シリカゲルが、毒性化合物が前記対象に侵入するのを防止するためのものである、請求項1記載の医薬組成物。
- 前記酸化防止剤が、アスコルビン酸、αトコフェロール又はγトコフェロールである、請求項1記載の医薬組成物。
- 軟膏剤である、請求項1記載の医薬組成物。
- 粘着ストリップに組み込まれる、請求項1記載の医薬組成物。
- 前記粘着ストリップが、軟膏剤用量の正確な測定のために、その一表面上に目盛り尺を有する、請求項5記載の医薬組成物。
- ガム又はロゼンジの形態である、請求項1記載の医薬組成物。
- ガス送達デバイスに組み込まれる、請求項1記載の医薬組成物。
- 前記送達デバイスが、吸入器又は鼻用カートリッジである、請求項1記載の医薬組成物。
- 前記粘着ストリップが、ホイルの裏地を更に含む、請求項5記載の医薬組成物。
- 前記ホイルの裏地が、一酸化窒素が外部環境に放出されるのを防止するためのものである、請求項10記載の医薬組成物。
- 前記治療量の一酸化窒素が、少なくとも1ppmである、請求項1記載の医薬組成物。
- 前記治療量の一酸化窒素が、少なくとも100ppmである、請求項1記載の医薬組成物。
- 前記治療量の一酸化窒素が、少なくとも200ppmである、請求項1記載の医薬組成物。
- 前記治療量の一酸化窒素が、少なくとも300ppmである、請求項1記載の医薬組成物。
- 前記一酸化窒素放出剤が、ポリマー及び少なくとも1の一酸化窒素放出N2O2 -官能基を有するポリマー組成物である、請求項1記載の組成物。
- 一酸化窒素放出組成物の製造方法であって、
固体マトリクス中の治療量の一酸化窒素放出剤を送達デバイスに組み込むことを含み、
該固体マトリクスが、シリカゲルと熱可塑性樹脂とを混合すること、得られた混合物を焼結すること、該固体マトリクスを酸化防止剤溶液でフラッシュすること、及び該固体マトリクスを乾燥させることによって形成される、前記製造方法。 - 前記送達デバイスが、吸入器、粘着ストリップ、軟膏剤、ガム又はロゼンジである、請求項18記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21920009P | 2009-06-22 | 2009-06-22 | |
US61/219,200 | 2009-06-22 | ||
PCT/US2010/039320 WO2010151505A1 (en) | 2009-06-22 | 2010-06-21 | Nitric oxide therapies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012530780A JP2012530780A (ja) | 2012-12-06 |
JP2012530780A5 JP2012530780A5 (ja) | 2013-08-08 |
JP5878866B2 true JP5878866B2 (ja) | 2016-03-08 |
Family
ID=43354591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517624A Active JP5878866B2 (ja) | 2009-06-22 | 2010-06-21 | 一酸化窒素治療 |
Country Status (6)
Country | Link |
---|---|
US (4) | US8613958B2 (ja) |
EP (1) | EP2445508B1 (ja) |
JP (1) | JP5878866B2 (ja) |
AU (1) | AU2010263098B2 (ja) |
CA (1) | CA2763804C (ja) |
WO (1) | WO2010151505A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618594B2 (en) * | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
EP2724742B1 (en) | 2004-08-18 | 2017-11-01 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
AU2006249323B2 (en) | 2005-05-27 | 2012-08-30 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
WO2009097343A1 (en) | 2008-01-28 | 2009-08-06 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
WO2010151505A1 (en) * | 2009-06-22 | 2010-12-29 | Geno Llc | Nitric oxide therapies |
DK2467173T3 (da) | 2009-08-21 | 2019-07-29 | Novan Inc | Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf |
CN102711729B (zh) | 2009-08-21 | 2015-04-01 | 诺万公司 | 局部用凝胶 |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
EP2681286B1 (en) | 2011-02-28 | 2018-08-15 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
EP2713723B1 (en) | 2011-05-27 | 2018-09-12 | Geno LLC | Method of determining vasoreactivity using inhaled nitric oxide |
CA2844910C (en) * | 2011-08-17 | 2017-07-11 | Board Of Regents, The University Of Texas System | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system |
MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
EP3585726B1 (en) | 2017-02-27 | 2022-09-21 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
CA3054660C (en) | 2017-02-27 | 2022-05-03 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
US11472705B2 (en) | 2018-03-13 | 2022-10-18 | Sanotize Research And Development Corp. | Nitric oxide releasing compositions |
US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
CA3109594A1 (en) | 2018-08-14 | 2020-02-20 | Sanotize Research And Development Corp. | Devices and methods for quantifying nitric oxide |
US11045620B2 (en) | 2019-05-15 | 2021-06-29 | Third Pole, Inc. | Electrodes for nitric oxide generation |
EP3969416A4 (en) | 2019-05-15 | 2023-11-01 | Third Pole, Inc. | SYSTEMS AND METHODS FOR GENERATING NITRIC OXIDE |
CN115151183A (zh) | 2020-01-11 | 2022-10-04 | 第三极股份有限公司 | 具有湿度控制的用于一氧化氮生成的系统和方法 |
WO2021178574A1 (en) * | 2020-03-05 | 2021-09-10 | Know Bio, Llc | Methods and systems for nitric oxide therapy for the treatment or prevention of respiratory infections |
US20210395905A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1021234A (en) | 1911-05-10 | 1912-03-26 | Hoechst Ag | Process of manufacturing pure nitric oxid. |
US2272810A (en) | 1937-03-10 | 1942-02-10 | Ici Ltd | Printing cellulosic textile materials |
US2696430A (en) | 1950-05-03 | 1954-12-07 | John A Gallaghan | Stabilizers for nitro-cellulose mixtures |
US3106458A (en) | 1960-12-14 | 1963-10-08 | Drager Otto H | Process for detecting nitrogen dioxide in gases |
GB1241858A (en) | 1968-12-30 | 1971-08-04 | Ici Ltd | Sorption of nitrogen dioxide by polyamides |
US3620685A (en) | 1969-07-30 | 1971-11-16 | Phillips Petroleum Co | Radial flow catalyst reactor |
US3958580A (en) | 1974-02-15 | 1976-05-25 | Hoffmann-La Roche Inc. | Treatment of tobacco with ascorbic acid |
NL7413636A (nl) | 1974-10-17 | 1976-04-21 | Shell Int Research | Werkwijze voor het vullen van een reactor met vaste deeltjes. |
US3930813A (en) | 1974-11-27 | 1976-01-06 | General Electric Company | Process for producing nitrogen dioxide-free oxygen-enriched gas |
US3979501A (en) | 1975-03-28 | 1976-09-07 | Meloy Laboratories, Inc. | Method and apparatus for converting nitrogen dioxide to nitric oxide |
US4010897A (en) | 1976-03-31 | 1977-03-08 | Charles F. Kettering Foundation | Method and apparatus for home production and application of nitrogen fertilizer |
NL7707839A (nl) | 1977-07-14 | 1979-01-16 | Philips Nv | Inrichting voor het kwantitatief reduceren van stikstofdioxyde in gasmengsels. |
IL57239A (en) | 1979-05-08 | 1982-04-30 | Alamaro Moshe | Production of nitric oxides |
US4778450A (en) | 1979-07-12 | 1988-10-18 | Baxter Travenol Laboratories, Inc. | Fluid flow control system |
US4270933A (en) | 1980-03-19 | 1981-06-02 | Meny Allan H | Regenerative, fluid filter |
US4433707A (en) | 1981-09-25 | 1984-02-28 | Chevron Research Company | Method and apparatus for level loading of vessels using catalyst oriented packing |
US4399942A (en) | 1981-11-09 | 1983-08-23 | Gc Industries | Gas emitting device |
FR2541588B1 (fr) | 1983-02-28 | 1985-07-05 | Air Liquide | Recipient et installation d'epuration par adsorption |
JPH0416198Y2 (ja) | 1984-11-02 | 1992-04-10 | ||
GB8516333D0 (en) | 1985-06-28 | 1985-07-31 | Johnson Matthey Plc | Nitric oxide |
US4822564A (en) | 1985-07-02 | 1989-04-18 | Sensors, Inc. | Chemiluminescent gas analyzer for measuring the oxides of nitrogen |
JPS6247371A (ja) | 1985-08-26 | 1987-03-02 | 帝人株式会社 | 酸素富化気体供給装置 |
DE3823381A1 (de) | 1987-11-03 | 1989-05-24 | Draegerwerk Ag | Kreislaufatemschutzgeraet |
US4963327A (en) | 1988-03-23 | 1990-10-16 | Z-Gard, Inc. | Oxygen generating module |
US4993436A (en) | 1989-12-21 | 1991-02-19 | Bloom Jr Walter L | Aspirating and volatilizing liquid dispenser |
US5683668A (en) | 1990-09-20 | 1997-11-04 | The United States Of America As Represented By The Department Of Health And Human Services | Method of generating nitric oxide gas using nitric oxide complexes |
US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
ES2288660T5 (es) | 1990-12-05 | 2015-05-29 | The General Hospital Corporation | Uso de NO para tratar la hipertensión pulmonar persistente del recién nacido |
US5206230A (en) | 1991-06-05 | 1993-04-27 | Daikin Industries, Ltd. | Fluorine-containing vitamin D3 analogues and pharmaceutical composition containing the same |
US5228434A (en) | 1991-07-16 | 1993-07-20 | Praxair Technology, Inc. | Mixture for anesthesia |
GB9120013D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method and apparatus for administering respirable pharmaceutical particles |
US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US6200558B1 (en) | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5525357A (en) | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
FR2695831B1 (fr) | 1992-09-24 | 1994-11-10 | Air Liquide | Installation et procédé de fourniture d'un mélange gazeux aux voies respiratoires d'un utilisateur. |
AU6232794A (en) | 1993-01-29 | 1994-08-15 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
JPH09502690A (ja) | 1993-09-13 | 1997-03-18 | アーゲーアー アクツイエボラーグ | 酸化窒素を製造する方法及び装置 |
US5670125A (en) | 1993-09-30 | 1997-09-23 | The Boc Group, Inc. | Process for the purification of nitric oxide |
GB9320978D0 (en) | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
US5558083A (en) | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
JPH07187622A (ja) | 1993-12-22 | 1995-07-25 | Osaka Gas Co Ltd | 低濃度noの製造方法及びno2の測定方法 |
US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
DE4419860A1 (de) | 1994-06-07 | 1995-12-14 | Hoechst Ag | Verfahren und Filter zur Herstellung von NO¶2¶-freiem Stickstoffmonoxid mit schwefelhaltigen Polymeren |
US5417950A (en) | 1994-07-07 | 1995-05-23 | The Boc Group, Inc. | Process for the purification of nitric oxide |
US5514204A (en) * | 1994-07-07 | 1996-05-07 | The Boc Group, Inc. | Process for the purification of nitric oxide |
US5583101A (en) | 1994-07-15 | 1996-12-10 | Harvard College | Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction |
US5615669A (en) | 1994-07-22 | 1997-04-01 | Siemens Elema Ab | Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject |
JPH0847534A (ja) | 1994-08-05 | 1996-02-20 | Naoki Yahagi | No吸入装置 |
US6190704B1 (en) | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
DE4437895C1 (de) | 1994-10-22 | 1996-05-09 | Draegerwerk Ag | Vorrichtung zur Erzeugung von Sauerstoff |
EP0788398A1 (de) * | 1994-10-25 | 1997-08-13 | Hoechst Aktiengesellschaft | Filtermaterial und verfahren zur herstellung von no2-freien gasen oder flüssigkeiten |
US5823180A (en) | 1995-04-03 | 1998-10-20 | The General Hospital Corporation | Methods for treating pulmonary vasoconstriction and asthma |
DE19517857C1 (de) | 1995-05-16 | 1996-05-09 | Ruesch Willy Ag | Beatmungsbeutel |
US5722392A (en) | 1995-05-19 | 1998-03-03 | University Of Florida | Breathable gas mixing devices, breathing systems and methods |
US6046383A (en) | 1995-09-11 | 2000-04-04 | Seminis Vegetable Seeds, Inc. | Cytoplasmic male sterile Brassica oleracea plants which contain the polima CMS cytoplasm and are male sterile at high and low temperatures |
US6158432A (en) | 1995-12-08 | 2000-12-12 | Cardiopulmonary Corporation | Ventilator control system and method |
ES2190467T3 (es) | 1996-02-27 | 2003-08-01 | Koster Henk W | Sistema de respiracion con un modulo de administracion de gas adicional. |
DE19612289A1 (de) | 1996-03-28 | 1997-10-02 | Messer Griesheim Gmbh | Verfahren und Vorrichtung zur Minderung von Risiken bei der inhalativen NO-Therapie |
US5692495A (en) | 1996-04-02 | 1997-12-02 | The Boc Group, Inc. | Method and apparatus for the production of nitric oxide gas mixture |
US5829428A (en) | 1996-05-29 | 1998-11-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for reducing the loss of respiratory promoters |
IN192791B (ja) | 1996-06-28 | 2004-05-22 | Johnson & Johnson Medical | |
SE506778C2 (sv) | 1996-08-12 | 1998-02-09 | Siemens Elema Ab | Förfarande vid blandning av gaser och en anordning för blandning av gaser |
US6039783A (en) | 1996-12-03 | 2000-03-21 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Process and equipment for nitrogen oxide waste conversion to fertilizer |
JPH10179742A (ja) | 1996-12-25 | 1998-07-07 | Sumitomo Seika Chem Co Ltd | 携帯用一酸化窒素−酸素ガス供給装置およびその操作方法 |
US6896899B2 (en) | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
US6086582A (en) | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
US5814129A (en) | 1997-04-11 | 1998-09-29 | Air Products And Chemical, Inc. | Radial flow adsorption vessel |
US6164276A (en) | 1997-05-16 | 2000-12-26 | Datex-Ohmeda, Inc. | Accurate dose nitric oxide pulse delivery device with monitoring and alarms |
CA2617349C (en) | 1997-06-17 | 2011-11-15 | Fisher & Paykel Healthcare Limited | Respiratory humidification system |
US5836362A (en) | 1997-07-15 | 1998-11-17 | Praxair Technology, Inc. | Multiple adsorbent loading method and apparatus for a radial flow vessel |
US5827420A (en) | 1997-07-29 | 1998-10-27 | World Precision Instruments, Inc. | Method and apparatus for the generation of nitric oxide |
US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
US6187937B1 (en) | 1998-01-16 | 2001-02-13 | Flexsys America L.P. | Preparation of N-phenyl-benzoquinoneimine from hydroxydiphenylamines |
US6109260A (en) | 1998-02-18 | 2000-08-29 | Datex-Ohmeda, Inc. | Nitric oxide administration device with timed pulse |
GB9812344D0 (en) | 1998-06-08 | 1998-08-05 | Euroflow Uk Ltd | Methods and apparatus for packing chromatography columns |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
WO2000011953A1 (en) | 1998-09-01 | 2000-03-09 | Penn State Research Foundation | Method and apparatus for aseptic growth or processing of biomass |
US20070086954A1 (en) | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
US6086659A (en) | 1999-01-29 | 2000-07-11 | Air Products And Chemicals, Inc. | Radial flow adsorption vessel |
US6576044B1 (en) | 1999-02-25 | 2003-06-10 | The Boc Group, Inc. | Process for the purification of nitric oxide |
US20050142218A1 (en) | 2000-03-09 | 2005-06-30 | Queen Mary & Westfield College | Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia |
GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
ATE408406T1 (de) | 1999-07-28 | 2008-10-15 | Univ Leland Stanford Junior | Verwendung von nikotin in der angiogenese und der vaskulogenese |
US20010012851A1 (en) | 1999-07-29 | 2001-08-09 | Kristin M. Lundy | Nitric oxide releasing oxindole prodrugs for anagesic, anti-inflammatory and disease-modifying use |
US6231824B1 (en) | 1999-08-10 | 2001-05-15 | The Boc Group, Inc. | Removal of nitric oxide from gas streams |
US6370911B1 (en) | 1999-08-13 | 2002-04-16 | Air Liquide America Corporation | Nitrous oxide purification system and process |
WO2001015738A2 (en) | 1999-09-02 | 2001-03-08 | Rice University | Nitric oxide-producing hydrogel materials |
AU780261B2 (en) | 1999-10-29 | 2005-03-10 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
US6270779B1 (en) | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
GB0022084D0 (en) | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
JP4590091B2 (ja) | 2000-11-24 | 2010-12-01 | 大陽日酸株式会社 | ガス分析装置 |
US7335181B2 (en) | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
EP1380538A4 (en) | 2001-04-17 | 2006-10-04 | Tokuyama Corp | METHOD FOR PRODUCING POROUS INORGANIC MATERIAL |
DE10119083C1 (de) | 2001-04-19 | 2002-11-28 | Joachim Alfred Wuenning | Kompakt-Dampf-Reformer |
US6749834B2 (en) | 2001-06-19 | 2004-06-15 | World Precision Instruments, Inc. | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies |
GB0117212D0 (en) * | 2001-07-16 | 2001-09-05 | Mat & Separations Tech Int Ltd | Filter element |
US6841166B1 (en) * | 2001-08-21 | 2005-01-11 | The Regents Of The University Of Michigan | Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives |
CA2459891C (en) | 2001-09-05 | 2014-02-04 | Cyterra Corporation | Method and apparatus for nitric oxide generation |
AU2002336761A1 (en) * | 2001-09-26 | 2003-04-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Nitric oxide-releasing coated medical devices and method of preparing same |
EP1323468A1 (en) | 2001-12-31 | 2003-07-02 | Grace GmbH & Co. KG | Adsorbing material comprised of porous functional solid incorporated in a polymer matrix |
US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
JP2003275583A (ja) | 2002-03-20 | 2003-09-30 | Hitachi Zosen Corp | 二酸化窒素吸収剤 |
CA2490392A1 (en) * | 2002-06-21 | 2003-12-31 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
JP2004065636A (ja) | 2002-08-07 | 2004-03-04 | Osaka Industrial Promotion Organization | 可搬型医療用一酸化窒素発生装置及び可搬型医療用一酸化窒素吸入装置 |
BRPI0412273B1 (pt) * | 2003-07-03 | 2019-09-24 | The University Court Of The University Of St. Andrews | Preparação farmacêutica, uso de um material de zeólito, artigo médico, produto cosmético e/ou de higiene pessoal, e, método de liberação de óxido nítrico |
US7282519B2 (en) | 2003-08-28 | 2007-10-16 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
JP3994079B2 (ja) | 2003-10-06 | 2007-10-17 | 株式会社タバタ | ダイビング用レギュレータ |
US20050217668A1 (en) | 2003-10-24 | 2005-10-06 | Pulmonox Technologies Corporation | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
US7125433B2 (en) * | 2003-12-31 | 2006-10-24 | Donaldson Company, Inc. | Dual diffusion channel filter |
US8017074B2 (en) | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
JP2005205320A (ja) | 2004-01-22 | 2005-08-04 | Mitsubishi Chemicals Corp | 固体触媒の充填方法 |
US7288664B2 (en) | 2004-03-30 | 2007-10-30 | Bela Kleiner | Reverse Kleiner method for manufacturing nitrogen dioxide, nitric oxide, nitric acid, metallic ascorbates and alkyl ascorbates of vitamin C |
US7407632B2 (en) | 2004-05-28 | 2008-08-05 | Oxysure Systems, Inc. | Apparatus and delivery of medically pure oxygen |
US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
EP2724742B1 (en) | 2004-08-18 | 2017-11-01 | Geno LLC | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US20070154570A1 (en) | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
CA2588744A1 (en) * | 2004-11-29 | 2006-06-01 | The University Of Akron | Topical nitric oxide donor devices and methods for their therapeutic use |
WO2006063056A1 (en) | 2004-12-07 | 2006-06-15 | Access Business Group International Llc | Methods for scavenging oxidizing nitrogen and oxygen species with fragrances having antioxidative properties |
AU2006249323B2 (en) * | 2005-05-27 | 2012-08-30 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
CA2820200C (en) * | 2005-06-09 | 2015-08-18 | Judith Esther Anderson | Compositions and methods for enhancing nitric oxide delivery |
US20070062532A1 (en) | 2005-09-21 | 2007-03-22 | Choncholas Gary J | Apparatus and method for identifying optimal PEEP |
EP1968584A2 (en) | 2005-12-20 | 2008-09-17 | Nitromed, Inc. | Nitric oxide enhancing glutamic acid compounds, compositions and methods of use |
US8790715B2 (en) * | 2006-02-16 | 2014-07-29 | Ino Therapeutics Llc | Method and apparatus for generating nitric oxide for medical use |
US8028692B2 (en) | 2006-03-09 | 2011-10-04 | Ric Investments, Llc | Multi-sectioned conduit assembly |
US8037880B2 (en) * | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
JP2009545384A (ja) | 2006-08-03 | 2009-12-24 | ブリーズ テクノロジーズ, インコーポレイテッド | 最小侵襲性呼吸補助のための方法および装置 |
US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
WO2008118360A1 (en) * | 2007-03-23 | 2008-10-02 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
JP5172940B2 (ja) * | 2007-03-27 | 2013-03-27 | ノーラブズ エービー | 一酸化窒素送達のための局所皮膚送達装置 |
WO2009097343A1 (en) | 2008-01-28 | 2009-08-06 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
US8701657B2 (en) | 2008-08-21 | 2014-04-22 | Geno Llc | Systems for generating nitric oxide |
US8607785B2 (en) * | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
JP5611955B2 (ja) | 2008-09-22 | 2014-10-22 | ゲノ エルエルシー | 二酸化窒素(no2)の一酸化窒素(no)への変換 |
WO2010151505A1 (en) * | 2009-06-22 | 2010-12-29 | Geno Llc | Nitric oxide therapies |
JP5995724B2 (ja) | 2009-11-20 | 2016-09-21 | ゲノ エルエルシー | 一酸化窒素送達システム |
JP5965845B2 (ja) | 2010-02-01 | 2016-08-10 | ゲノ エルエルシー | 一酸化窒素送達システム |
EP2563435B1 (en) | 2010-04-26 | 2020-06-03 | VERO Biotech LLC | Delivery of ultra pure nitric oxide (no) |
CA2797674C (en) | 2010-04-26 | 2018-06-12 | Geno Llc | Nitrosyl special connector |
US8313561B2 (en) | 2010-10-05 | 2012-11-20 | Praxair Technology, Inc. | Radial bed vessels having uniform flow distribution |
EP2646365B1 (en) | 2010-12-03 | 2016-08-03 | Koninklijke Philips N.V. | Method and arrangement for generating nitric oxide |
CA2991860C (en) | 2011-01-06 | 2020-03-24 | Mallinckrodt Hospital Products IP Limited | Gas delivery device and system |
EP2713723B1 (en) | 2011-05-27 | 2018-09-12 | Geno LLC | Method of determining vasoreactivity using inhaled nitric oxide |
JP5755258B2 (ja) | 2013-01-07 | 2015-07-29 | 本田技研工業株式会社 | 車体側部構造 |
US20140373836A1 (en) | 2013-06-25 | 2014-12-25 | Ino Therapeutics Llc | Methods of Reducing the Risk of Mortality Associated With a Medical Treatment |
-
2010
- 2010-06-21 WO PCT/US2010/039320 patent/WO2010151505A1/en active Application Filing
- 2010-06-21 EP EP10792554.7A patent/EP2445508B1/en active Active
- 2010-06-21 US US12/819,670 patent/US8613958B2/en active Active
- 2010-06-21 AU AU2010263098A patent/AU2010263098B2/en not_active Ceased
- 2010-06-21 JP JP2012517624A patent/JP5878866B2/ja active Active
- 2010-06-21 CA CA2763804A patent/CA2763804C/en active Active
-
2013
- 2013-12-21 US US14/138,061 patent/US9192718B2/en active Active
-
2015
- 2015-11-23 US US14/948,992 patent/US11103669B2/en active Active
-
2021
- 2021-08-30 US US17/461,484 patent/US11925764B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9192718B2 (en) | 2015-11-24 |
US11103669B2 (en) | 2021-08-31 |
CA2763804C (en) | 2018-02-06 |
US20140236073A1 (en) | 2014-08-21 |
EP2445508A1 (en) | 2012-05-02 |
JP2012530780A (ja) | 2012-12-06 |
US20160151598A1 (en) | 2016-06-02 |
EP2445508A4 (en) | 2012-12-05 |
AU2010263098B2 (en) | 2016-01-07 |
US11925764B2 (en) | 2024-03-12 |
US8613958B2 (en) | 2013-12-24 |
EP2445508B1 (en) | 2018-11-14 |
US20220088342A1 (en) | 2022-03-24 |
AU2010263098A1 (en) | 2011-12-08 |
WO2010151505A1 (en) | 2010-12-29 |
CA2763804A1 (en) | 2010-12-29 |
US20100323036A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5878866B2 (ja) | 一酸化窒素治療 | |
US8066904B2 (en) | Controlled generation of nitric oxide | |
Shin et al. | Inorganic/organic hybrid silica nanoparticles as a nitric oxide delivery scaffold | |
Sharma et al. | Chronic treatment with nanoparticles exacerbate hyperthermia induced blood-brain barrier breakdown, cognitive dysfunction and brain pathology in the rat. Neuroprotective effects of nanowired-antioxidant compound H-290/51 | |
RU2002134467A (ru) | Способ высокоэффективной доставки аэрозоля с большой терапевтической массой | |
CA2662777A1 (en) | Methods and systems of delivering medication via inhalation | |
Yang et al. | Recent advances in upconversion nanoparticle-based nanocomposites for gas therapy | |
US8575218B2 (en) | Thiol-containing compounds for the removal of elements from tissues and formulations therefor | |
RU2005116680A (ru) | Адсорбент для перорального введения и средство для лечения или тпредупреждения заболевания почек или печени | |
Gong et al. | Therapeutic gas delivery strategies | |
RU99118589A (ru) | Новый препарат для ингаляции, имеющий насыпную объемную плотность от 0,28 до 0,38 г/мл, содержащий будесонид | |
WO2015014209A1 (zh) | 稳定渗透压的丙酮酸药物组成及其在健康人和肺病病人中的排毒作用 | |
JPH01185267A (ja) | 新吸入器 | |
KR20060003072A (ko) | 정맥주사용 활성탄 주입액, 그 제조방법 및 이의 암치료약물의 사용방법 | |
US20220273814A1 (en) | C60 glutathione dopa and methods | |
CN113549611B (zh) | 一种级联纳米酶及其制备方法与应用 | |
CN104274832B (zh) | 一种可作为药物载体的单分散多孔杂化材料纳米微球及其制备方法 | |
WO2023107144A1 (en) | Nitric oxide c60-gsh-atp and use | |
CN101434646A (zh) | 两性化合物及其应用 | |
US20210046108A1 (en) | Dissolved c60 and method of producing dissolved c60 | |
RU97119947A (ru) | Квантодепрессантное средство лечения онкологических болезней крови, легких, печени и других органов | |
AU676996B2 (en) | Use of aqueous solutions containing peroxobisulphate ions for the treatment of malignant cells | |
CN101822654A (zh) | 喷替酸盐吸入剂 | |
TH54458A3 (th) | สารสูตรผสมชนิดของเหลวที่มีฟอร์โมเทรอล ซึ่งเหมาะสมสำหรับการเก็บรักษา |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130620 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140701 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140924 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150706 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160129 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5878866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |